Oncology Xagena

Xagena Mappa
Xagena Newsletter
Medical Meeting

Primary gastrointestinal stromal tumor: Imatinib decreases cancer recurrence

Preliminary results from a large, randomized, placebo-controlled clinical trial for patients with primary gastrointestinal stromal tumor ( GIST ), a type of tumor usually found in the stomach or small intestine, showed that patients who received Imatinib ( Glivec / Gleevec ) after complete removal of their tumor were significantly less likely to have a recurrence of their cancer compared to those who did not receive Imatinib.

The clinical trial was sponsored by the National Cancer Institute ( NCI ), part of the National Institutes of Health ( NIH ), and conducted by a network of researchers led by the American College of Surgeons Oncology Group ( ACOSOG ).